



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 BH10 Pol Expression Vector (pPolo)

Catalog Number: 238

Lot Number: 1934

Release Category: A

Provided: 1 ml (6.8×10^9) of ampicillin-resistant transformed HB101 bacteria. Cells are suspended in LB medium supplemented with 50 µg/ml ampicillin and 15% glycerol.

Description: Derived from BH10. Contains a 4978 bp BglIII insert (nt 2093-7071) cloned into pEXc13, a pBR322 derivative. Pol ORF extends from nt 2093-5126.

Special Characteristics: Contains a BglIII insert of 4978 bp from HIV-1BH10, seq. 2093-7071 cloned into pExc13 (derived from pBR322). Pol ORF extends from 2093-5126. Contains ampr marker. Pol sequences are induced following removal of tryptophan from growing cultures. Induced proteins are detected optimally 2-3 hours after induction (37°C). Produces protease and reverse transcriptase.

[Plasmid Map](#)

Recommended Storage: -70°C.

Contributor: Dr. Bruce Korant.

References: Danley DE, Geoghegan KF, Scheld KG, Lee S, Merson JR, Hawrylik SJ, Rickett GA, Ammirati MJ, Hobart PM. Crystallizable HIV-1 protease derived from expression of the viral *pol* gene in *Escherichia coli*. *Biochem Biophys Res Commun* **165**:1043-1050, 1989.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Ivanoff LA, Towatari T, Ray J, Korant BD, Petteway SR Jr. Expression and site-specific mutagenesis of the poliovirus 3C protease in *Escherichia coli*. *Proc Natl Acad Sci USA* **83**:5392-5396, 1986.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 BH10 Pol Expression Vector (pPolo) from Dr. Bruce Korant (cat# 238)." Also include the references cited above in any publications.

Last Updated:

August 01, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.